Nastech files application for anti-obesity nasal spray

By Elaine Rigoli

Tampa, Fla., June 7 - Nastech Pharmaceutical Co., Inc. submitted an Investigational New Drug application to the Food and Drug Administration for PYY3-36 (PYY) nasal spray, the company's lead investigational product candidate for the treatment of obesity.

Nastech said the filing of the IND precedes the start of clinical studies in the United States.

The study included in the IND is designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various dosing regimens of PYY nasal spray in obese subjects.

The objective of study is to determine the optimal dosing regimens that will be used to conduct a phase 2 clinical study based on the initial trial, according to a news release.

Peptide YY is a naturally occurring hormone that is believed to function as a physiologic inhibitor of food intake, the release said.

Nastech is a pharmaceutical company with headquarters in Bothell, Wash.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.